Announcements
- Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
- Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
- Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
- Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
- Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
More ▼
Key statistics
As of last trade Gyre Therapeutics Inc (L9S:STU) traded at 10.40, -32.90% below its 52-week high of 15.50, set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.40 |
---|---|
High | 10.40 |
Low | 10.40 |
Bid | 11.20 |
Offer | 11.90 |
Previous close | 10.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 85.51m |
Free float | 15.62m |
P/E (TTM) | -- |
Market cap | 1.06bn USD |
EPS (TTM) | -1.88 USD |
Data delayed at least 15 minutes, as of Jul 05 2024.
More ▼